US EPA

1352496 

Journal Article 

Sodium stibogluconate: Therapeutic use in the management of leishmaniasis 

Roychoudhury, J; Ali, N 

2008 

1 

Indian Journal of Biochemistry and Biophysics
ISSN: 0301-1208
EISSN: 0975-0959 

45 

1 

16-22 

WOS:000256436800002 

Leishmaniasis causes significant morbidity and mortality
worldwide. The disease is endemic in developing countries of tropical regions, and in recent
years economic globalization and increased travel has also spread to people in developed
countries. In the absence of effective vaccines and vector-control measures, the main line of
defense against the disease is chemotherapy. Organic pentavalent antimonials, including sodium
stibogluconate have been the first-line drug for the treatment of leishmaniasis for the last
several decades, and clinical resistance to these drugs has emerged as a primary obstacle to
successful treatment and control. The present review describes the Structure, activity, mode of
action of sodium stibogluconate and mechanism of resistance towards this drug in leishmaniasis. 

sodium stibogluconte; visceral leishmaniasis; resistance; pentavalent antimonials